START MR Trials
| ProfoundBio PRO1184 | |
| Description | This is a Phase 1/2 study of PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1184 in patients with selected locally advanced and/or metastatic solid tumors |
| Target Population | Ovarian cancer
Endometrial cancer NSCLC Breast cancer Mesothelioma |
| Type of medication | Intravenous infusion |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05579366?term=pro1184&draw=2&rank=1 |
| Aadi HEP-001 | |
| Description | This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function |
| Target Population | Advanced solid tumors |
| Type of medication | Intravenous infusion, Days 1 and 8 |
| Phase of study | I |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05661461?term=Hep-001&draw=2&rank=2 |
| Alkermes ALKS4230-003 | |
| Description | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients |
| Target Population | Biliary tract tumor
Cervical cancer Cutaneous melanoma Endometrial cancer Esophageal cancer gastric and GEJ adenocarcinoma, Head and neck SCC Metastatic or advanced breast cancer • after treatment failure or intolerance of 1 to 3 established indication‑specific therapies Mucosal melanoma NSCLC Ovarian cancer Pancreatic cancer Small cell lung cancer |
| Type of medication | Intravenous medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT04592653?term=ALKS4230-003&draw=2&rank=1 |
| Arcus AB308_AB122 | |
| Description | A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies |
| Target Population | Cervical cancer
DLBCL (2 prior lines of therapy) Esophageal cancer Gastric cancer Melanoma MM NSCLC |
| Type of medication | Intravenous medication |
| Phase of study | I/Ib |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT04772989?cntry=US&state=US%3AUT&city=West+Valley+City&draw=4 |
| Gilead GS-9716 | |
| Description | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies |
| Target Population | Adenocarcinoma
Breast cancer Castrate resistant prostate cancer (CRPC) Cervical cancer Colorectal cancer Endometrial cancer Follicular thyroid cancer Gastric or gastroesophageal cancer Head and neck SCC Hepatocellular carcinoma NSCLC Ovarian cancer Renal cell cancer Small cell lung cancer Urothelial cancer |
| Type of medication | Oral medication |
| Phase of study | I |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/study/NCT05006794?term=GS-9716&draw=2&rank=1 |
| Inhibrx INBRX-105 | |
| Description | INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism. |
| Target Population | Gastric cancer
GEJ cancer Head and neck SCC Melanoma NSCLC Renal cell Urothelial cancer Locally advanced or metastatic disease, failed standard therapy or no standard therapy |
| Type of medication | Intravenous medications |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/record/NCT03809624?term=Start+mountain+region&cntry=US&state=US%3AUT&city=West+Valley+City&draw=2 |
| Jounce JTX-4014 | |
| Description | JTX-8064 is a humanized mAb designed to block the interaction of LILRB2 with its known ligands, endogenous major histocompatibility complex class I (MHC I) molecules. This is a dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i). |
| Target Population | Renal cell cancer
Triple negative breast cancer Head and neck SCC NSCLC Cutaneous SCC Un-differentiated pleomorphic sarcoma Liposarcoma |
| Type of medication | Intravenous medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT04669899?term=Start+mountain+region&cntry=US&state=US%3AUT&city=West+Valley+City&draw=2 |
| Loxo LOXO-RAS-2001 | |
| Description | Phase 1 study to evaluate safety, tolerability, and preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors. |
| Target Population | Tumors with KRAS G12C mutation |
| Type of medication | Oral medication |
| Phase of study | I |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT04956640?term=Start+mountain+region&cntry=US&state=US%3AUT&city=West+Valley+City&draw=2 |
| Merus MCLA-129 | |
| Description | Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors |
| Target Population | Adenocarcinoma
Advanced cancer • EFGR mutated/MET mutated/Amplified Gastric/GEJ cancer • EFGR mutated/MET mutated/Amplified Head and neck SCC |
| Type of medication | Intravenous medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT04868877?term=Start+mountain+region&cntry=US&state=US%3AUT&city=West+Valley+City&draw=2 |
| Seagen SGNALPV | |
| Description | This study will test the safety of a drug called SGN-ALPV, a novel investigational antibody–drug conjugate directed to ALPP and/or ALPPL2, in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. |
| Target Population | Cervical cancer
Endometrial cancer Gastric cancer NCSLC Ovarian GCT Ovarian cancer Testicular germ cell tumor |
| Type of medication | Intravenous medication |
| Phase of study | I |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/study/NCT05229900?term=seagen&phase=0&draw=2 |
| Seagen SGNB7H4V-001 | |
| Description | This study will test the safety of a drug called SGN-B7H4V, a novel investigational antibody–drug conjugate directed to B7-H4, in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. |
| Target Population | Breast cancer (HER2-negative, HR-positive)
Breast cancer (triple negative) Cholangiocarcinoma Endometrial carcinoma Gallbladder carcinoma High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer Sq-NSCLC |
| Type of medication | Intravenous medication |
| Phase of study | I |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05194072?draw=2 |
| Treadwell TWT-203 | |
| Description | This study will be evaluating the safety and tolerability of CFI-402257, Selective TTK Inhibitor, in subjects with advanced solid tumors and in advanced breast cancer. |
| Target Population | Advanced malignancy
Breast Cancer ER+ and/or PR+ and HER2- |
| Type of medication | Oral medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05251714 |
| Bristol Myers Squibb
BMS-986360/CC-90001 |
|
| Description | The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors. |
| Target Population | Head and Neck SCC
MSS colorectal carcinoma NSCLC Pancreatic adenocarcinoma Renal cell carcinoma Sarcoma Triple negative breast cancer |
| Type of medication | Oral medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05625412 |
| Surface SRF114-101 | |
| Description | This is a Phase 1/2, open-label, first-in-human, dose-escalation and expansion study of SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with advanced solid tumors |
| Target Population | Advanced solid tumor |
| Type of medication | IV Medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05635643 |
| Profound Bio PRO1160-001 | |
| Description | This is a Phase 1/2 study of PRO1160, a CD70 targerd antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1184 in patients with selected locally advanced and/or metastatic solid tumors |
| Target Population | Renal cell carcinoma
Nasopharyngeal carcinoma Non-Hodgkin lymphoma |
| Type of medication | IV Medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05721222 |
| Totus TOS-358-001 | |
| Description | TOS-358, a first-in-class covalent PI3Kα inhibitor, in patients with various solid tumors with known PI3Kα mutations |
| Target Population | Cervical Cancer
Colorectal Cancer Endometrial Cancer Gastric Cancer HER2-negative Breast Cancer Non-small Cell Lung Cancer Ovarian Cancer Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma
*With known PIK3CA mutation or amplifications |
| Type of medication | Oral Medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05683418 |
| Ideaya IDA161-001 | |
| Description | Phase 1 clinical trial evaluating IDE161 a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as poly (ADP-ribose) polymerase (PARP) |
| Target Population | Any solid tumor malignancy with documented evidence (NGS testing) of one of the following:
· BRCA 1/2 alterations · HRD alterations (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, NBN, and/or FANCA) |
| Type of medication | Oral Medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05787587 |
| Sensei SNS-101-2-1 | |
| Description | Phase 1/2 clinical trial evaluating SNS-101 for the treatment of advanced solid tumors. SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1. |
| Target Population | Advanced solid tumor |
| Type of medication | IV Medication |
| Phase of study | I/II |
| Available at | START Mountain Region |
| Link | https://clinicaltrials.gov/ct2/show/NCT05864144 |